$26.80
0.30% yesterday
NYSE, Jan 13, 10:11 pm CET
ISIN
US7170811035
Symbol
PFE
Sector
Industry

Pfizer Stock price

$26.80
+1.22 4.77% 1M
-2.30 7.90% 6M
+0.27 1.02% YTD
-1.90 6.62% 1Y
-28.74 51.75% 3Y
-10.53 28.21% 5Y
-3.93 12.79% 10Y
NYSE, Closing price Mon, Jan 13 2025
+0.08 0.30%
ISIN
US7170811035
Symbol
PFE
Sector
Industry

Key metrics

Market capitalization $151.42b
Enterprise Value $209.44b
P/E (TTM) P/E ratio 35.92
EV/FCF (TTM) EV/FCF 25.46
EV/Sales (TTM) EV/Sales 3.48
P/S ratio (TTM) P/S ratio 2.52
P/B ratio (TTM) P/B ratio 1.64
Dividend yield 6.32%
Last dividend (FY24) $1.69
Revenue growth (TTM) Revenue growth -12.29%
Revenue (TTM) Revenue $60.11b
EBIT (operating result TTM) EBIT $9.81b
Free Cash Flow (TTM) Free Cash Flow $8.23b
Cash position $9.95b
EPS (TTM) EPS $0.74
P/E forward 17.26
P/S forward 2.41
EV/Sales forward 3.33
Short interest 1.51%
Show more

Is Pfizer a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,896 stocks worldwide.

Pfizer Stock Analysis

Unlock Scores for Free

Analyst Opinions

26 Analysts have issued a Pfizer forecast:

12x Buy
46%
13x Hold
50%
1x Sell
4%

Analyst Opinions

26 Analysts have issued a Pfizer forecast:

Buy
46%
Hold
50%
Sell
4%

Financial data from Pfizer

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
60,113 60,113
12% 12%
100%
- Direct Costs 24,944 24,944
22% 22%
41%
35,169 35,169
3% 3%
59%
- Selling and Administrative Expenses 7,970 7,970
4% 4%
13%
- Research and Development Expense 10,494 10,494
8% 8%
17%
16,705 16,705
0% 0%
28%
- Depreciation and Amortization 6,892 6,892
12% 12%
11%
EBIT (Operating Income) EBIT 9,813 9,813
7% 7%
16%
Net Profit 4,273 4,273
59% 59%
7%

In millions USD.

Don't miss a Thing! We will send you all news about Pfizer directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Pfizer Stock News

Positive
Seeking Alpha
43 minutes ago
This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 billion by 2028. Every year, the FDA and EMA approve dozens of anticancer drugs, so Seeking Alpha readers should be careful when making decisions.
Neutral
Seeking Alpha
about 3 hours ago
Pfizer Inc. (NYSE:PFE ) 43rd Annual J.P. Morgan Healthcare Conference Call January 13, 2025 12:45 PM ET Company Participants Albert Bourla - Chairman & Chief Executive Officer Conference Call Participants Chris Schott - JPMorgan Chris Schott Good morning, everybody.
Positive
Reuters
about 5 hours ago
U.S. drugmaker Pfizer is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that area, Chief Exeuctive Officer Albert Bourla said at the JPMorgan Healthcare conference on Monday.
More Pfizer News

Company Profile

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Head office United States
CEO Albert Bourla
Employees 88,000
Founded 1849
Website www.pfizer.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today